Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDRX NASDAQ:CDT NASDAQ:ENTO NASDAQ:SLXN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$3.26+0.6%$3.62$2.86▼$66.50$6.42M1.15501,712 shs19,394 shsCDTCDT Equity$1.05-13.9%$5.50$0.99▼$878.00$5.18M1.685,112 shs298,233 shsENTOEntero Therapeutics$4.61+20.1%$2.54$0.32▼$5.84$7.32M1.192.80 million shs169,216 shsSLXNSilexion Therapeutics$0.49+2.9%$0.99$0.23▼$22.36$1.61M-0.293.57 million shs2.43 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals+4.18%-4.71%-19.00%-44.14%-95.02%CDTCDT Equity-0.81%-34.41%-63.14%-93.49%-99.87%ENTOEntero Therapeutics-0.26%+11.30%+37.63%+31.51%+224.05%SLXNSilexion Therapeutics-10.34%-4.77%-52.50%-69.55%-96.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$3.26+0.6%$3.62$2.86▼$66.50$6.42M1.15501,712 shs19,394 shsCDTCDT Equity$1.05-13.9%$5.50$0.99▼$878.00$5.18M1.685,112 shs298,233 shsENTOEntero Therapeutics$4.61+20.1%$2.54$0.32▼$5.84$7.32M1.192.80 million shs169,216 shsSLXNSilexion Therapeutics$0.49+2.9%$0.99$0.23▼$22.36$1.61M-0.293.57 million shs2.43 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals+4.18%-4.71%-19.00%-44.14%-95.02%CDTCDT Equity-0.81%-34.41%-63.14%-93.49%-99.87%ENTOEntero Therapeutics-0.26%+11.30%+37.63%+31.51%+224.05%SLXNSilexion Therapeutics-10.34%-4.77%-52.50%-69.55%-96.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDRXBiodexa Pharmaceuticals 1.00SellN/AN/ACDTCDT Equity 1.00SellN/AN/AENTOEntero Therapeutics 1.00SellN/AN/ASLXNSilexion Therapeutics 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest SLXN, BDRX, ENTO, and CDT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/29/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)3/27/2026CDTCDT Equity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/18/2026SLXNSilexion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDRXBiodexa Pharmaceuticals$470K13.94N/AN/A$110.30 per share0.03CDTCDT EquityN/AN/AN/AN/A($77.82) per shareN/AENTOEntero TherapeuticsN/AN/AN/AN/A($2.45) per shareN/ASLXNSilexion TherapeuticsN/AN/AN/AN/A$0.09 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDRXBiodexa Pharmaceuticals-$8.42MN/AN/AN/AN/AN/AN/AN/AN/ACDTCDT Equity-$39.22M-$66,338.55N/AN/AN/AN/A-4,263.33%-529.91%N/AENTOEntero Therapeutics-$18.06M-$1.69N/AN/AN/AN/A-461.02%-14.72%N/ASLXNSilexion Therapeutics-$11.91M-$8.05N/AN/AN/AN/A-516.86%-176.68%N/ALatest SLXN, BDRX, ENTO, and CDT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026SLXNSilexion Therapeutics-$1.29-$0.85+$0.44$0.85N/AN/A3/27/2026Q4 2025BDRXBiodexa Pharmaceuticals-$0.0066$3.5250+$3.5316-$5.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/ACDTCDT EquityN/AN/AN/AN/AN/AENTOEntero TherapeuticsN/AN/AN/AN/AN/ASLXNSilexion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDRXBiodexa PharmaceuticalsN/A2.032.03CDTCDT EquityN/A0.340.34ENTOEntero TherapeuticsN/A2.622.62SLXNSilexion TherapeuticsN/A1.002.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDRXBiodexa Pharmaceuticals17.51%CDTCDT Equity3.29%ENTOEntero Therapeutics12.30%SLXNSilexion Therapeutics10.95%Insider OwnershipCompanyInsider OwnershipBDRXBiodexa Pharmaceuticals0.34%CDTCDT Equity10.78%ENTOEntero Therapeutics0.75%SLXNSilexion Therapeutics5.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDRXBiodexa Pharmaceuticals202.00 million1.99 millionNot OptionableCDTCDT Equity34.86 million4.33 millionNot OptionableENTOEntero Therapeutics91.59 million3.34 millionN/ASLXNSilexion TherapeuticsN/A3.33 million3.16 millionN/ASLXN, BDRX, ENTO, and CDT HeadlinesRecent News About These CompaniesSilexion Therapeutics Corp SLXNMay 20 at 6:38 PM | morningstar.comMBiotech Stock Silexion Therapeutics Corp. (NASDAQ: SLXN) Soars on Update and First Quarter ResultsMay 20 at 6:38 PM | investorideas.comISilexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financingMay 20 at 1:50 PM | quiverquant.comQSilexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 18, 2026 | globenewswire.comSilexion Therapeutics Announces Exercise of Warrants for $1 Million Gross ProceedsMay 15, 2026 | globenewswire.comSilexion Therapeutics Reports Positive Preclinical Results for SIL204 in KRAS-Mutated Pancreatic Cancer StudyMay 14, 2026 | quiverquant.comQSilexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic CancerMay 14, 2026 | globenewswire.comSilexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky ...May 13, 2026 | markets.businessinsider.comSilexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical CenterMay 13, 2026 | globenewswire.comSilexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic CancerApril 28, 2026 | markets.businessinsider.comSilexion Therapeutics Submits Clinical Trial Application for SIL204 in Phase 2/3 Trial for Locally Advanced Pancreatic Cancer in GermanyApril 28, 2026 | quiverquant.comQSilexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic CancerApril 28, 2026 | globenewswire.comSilexion Therapeutics (SLXN) price target decreased by 33.33% to 6.12March 27, 2026 | msn.comSilexion Therapeutics Announces Immediate Board Membership ChangeMarch 25, 2026 | tipranks.comSilexion Therapeutics Corp: Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced ...March 24, 2026 | finanznachrichten.deSilexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerMarch 24, 2026 | globenewswire.comSilexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerMarch 24, 2026 | globenewswire.comSilexion Therapeutics Corp: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 20, 2026 | finanznachrichten.deSilexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 17, 2026 | globenewswire.comSilexion Therapeutics to Participate in 7th RNAi-Based Therapeutics Summit Focused on Advancing SIL204 for Pancreatic CancerJanuary 21, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026STMicronelectronics Sends Industrial Chips Into OverdriveBy Thomas Hughes | April 24, 2026Harley Pivots Hard: Can New Bikes Fix an Old Brand?By Jeffrey Neal Johnson | May 9, 2026SLXN, BDRX, ENTO, and CDT Company DescriptionsBiodexa Pharmaceuticals NASDAQ:BDRX$3.26 +0.02 (+0.59%) As of 03:55 PM Eastern This is a fair market value price provided by Massive. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.CDT Equity NASDAQ:CDT$1.05 -0.17 (-14.10%) As of 03:58 PM Eastern This is a fair market value price provided by Massive. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Entero Therapeutics NASDAQ:ENTO$4.61 +0.77 (+20.05%) As of 05/21/2026Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Silexion Therapeutics NASDAQ:SLXN$0.49 +0.01 (+2.95%) As of 03:57 PM Eastern This is a fair market value price provided by Massive. Learn more.Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
